GERMANTOWN, Md., Jan. 6, 2015 /PRNewswire/ -- Neuralstem,
Inc. (NYSE MKT: CUR) announced that the Company will present at the
seventh annual Biotech Showcase in San
Francisco on Tuesday, January
13, at 9:00 a.m. PST.
Richard Garr, President and CEO,
will present an overview on the company's clinical advancements of
2014 for both the cell therapy and small molecule drug discovery
pipeline platforms. This will include the status of the company's
lead cell therapy asset, NSI-566 for amyotrophic lateral sclerosis
(ALS), and its lead neurogenic small molecule program, NSI-189, for
the treatment of major depressive disorder.
A live audio webcast of the presentation will be available by
visiting the Investor Center home page of Neuralstem's website:
investor.neuralstem.com. An archive of the presentation will
also be available for 30 days.
For more information on Biotech Showcase 2015, visit:
http://www.ebdgroup.com/bts/index.php.
About Neuralstem
Neuralstem's patented technology enables the production of
multiple types of brain and spinal cord neural stem cells in
commercial quantities for the potential treatment of central
nervous system diseases and conditions. Neuralstem's first stem
cell product, NSI-566, a spinal cord-derived neural stem cell line,
is in an ongoing clinical trial to treat amyotrophic lateral
sclerosis (ALS, or Lou Gehrig's
disease). Phase II surgeries were completed in July, 2014. A later
stage trial is anticipated to commence in 2015 at multiple centers.
Neuralstem received orphan status designation by the FDA for
NSI-566 in ALS. In addition to ALS, NSI-566 is also in a Phase I
trial in chronic spinal cord injury at UC San Diego School of
Medicine. NSI-566 is also in clinical development to treat
neurological diseases such as ischemic stroke and acute spinal cord
injury.
Neuralstem's second stem cell product, NSI-532.IGF, consists of
human cortex-derived neural stem cells that have been engineered to
secrete human insulin-like growth factor 1 (IGF-1). In animal data
presented at the Congress of Neurological Surgeons 2014 Annual
Meeting, the cells rescued spatial learning and memory deficits in
an animal model of Alzheimer's disease.
Additionally, Neuralstem's ability to generate human neural stem
cell lines for chemical screening has led to the discovery and
patenting of compounds that may stimulate the brain's capacity to
generate neurons, possibly reversing pathologies associated with
certain central nervous system (CNS) conditions. The company
has completed Phase Ia and Ib trials evaluating NSI-189, its first
neurogenic small molecule product candidate, for the treatment of
major depressive disorder (MDD), and is expecting to launch a Phase
II study for major depressive disorder (MDD) in 2015. Additional
indications might include traumatic brain injury (TBI), Alzheimer's
disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect
with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward Looking Information:
This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements in this press release regarding
potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31, 2013 and Form 10Q, for the period
ended September 30, 2014.
Logo -
http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neuralstem-to-present-at-biotech-showcase-2015-300016195.html
SOURCE Neuralstem, Inc.